Citigroup maintains Buy rating on ArriVent BioPharma
Valid market news retained in the public archive without immediate LiveCast distribution.
Story updates
07:21:22 PM UTC
SquawkNews
ArriVent BioPharma Price Target Cut to $20.00/Share From $40.00 by Citigroup